Lantheus控股 LNTH 深 滬
已收盤 11-14 16:00:00 美东时间
53.01
-0.110
-0.21%
華盛通- 最 高53.11
- 今 開51.99
- 成交量 88.38万股
- 最 低 51.47
- 昨 收 53.12
- 總市值 36.04亿
- 52周最高 111.29
- 市盈率 靜 12.16
- 換手率 1.30%
- 52周最低 47.25
- 委 比 -18.78%
- 總股本 6799.41万
- 歷史最高 126.8899
- 量 比 0.64
- 振 幅 3.09%
- 歷史最低 1.76
- 每 手 1
- 風險率 17.45%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
11-11 10:49
Lantheus Holdings Narrows FY2025 Adj EPS Guidance from $5.50-$5.70 to $5.50-$5.65 vs $5.63 Est; Raises FY2025 Sales Guidance from $1.475B-$1.510B to $1.490B-$1.510B vs $1.483B Est
Lantheus Holdings (NASDAQ:LNTH) narrows FY2025 Adj EPS guidance from $5.50-$5.70 to $5.50-$5.65 vs $5.63 analyst estimate. Raises FY2025 sales outlook from $1.475 billion-$1.510 billion to $1.490 billion-$1.510 billion
11-06 20:19
Lantheus CEO Brian Markison To Retire, Effective Dec. 31; Mary Anne Heino Appointed Executive Chairperson, Interim CEO, Effective Nov. 7; President Paul Blanchfield Departing
Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today
11-06 20:19
Lantheus Holdings Q3 Adj. EPS $1.27 Beats $1.26 Estimate, Sales $384.014M Beat $363.365M Estimate
Lantheus Holdings (NASDAQ:LNTH) reported quarterly earnings of $1.27 per share which beat the analyst consensus estimate of $1.26 by 0.47 percent. This is a 25.29 percent decrease over earnings of $1.70 per share from
11-06 20:18
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
Lantheus Announces Leadership Transition Plan
Lantheus Holdings, Inc. announces that CEO Brian Markison will retire on December 31, 2025, after 13 years of service. The board has started a search for a new CEO, with Markison staying on as a strategic advisor until March 2026. Mary Anne Heino, former CEO, will serve as Executive Chairperson and interim CEO until a permanent replacement is found. Paul Blanchfield, the company's President, is leaving to join another firm, and Amanda Morgan will...
11-06 12:00
Lantheus Announces FDA Acceptance of New Drug Application for MK-6240, a PET Imaging Agent Targeting Tau in Alzheimer’s Disease
The FDA has accepted Lantheus' NDA for MK-6240, an F18-labeled PET imaging agent targeting tau neurofibrillary tangles in Alzheimer's disease. The PDUFA target action date is August 13, 2026. MK-6240 previously received Fast Track designation and has shown promise in detecting tau pathology, with pivotal Phase 3 trials meeting sensitivity and specificity endpoints. Lantheus highlights the potential of MK-6240 to address unmet diagnostic needs in ...
10-28 12:30
Investors Turn to AI-Driven Imaging Firms Targeting High-Growth Breast Cancer Market
NetworkNewsWire Editorial Coverage NEW YORK, Oct. 23, 2025 /PRNewswire/ -- Artificial intelligence (AI) continues to transform healthcare innovation, with medical imaging emerging as one of ...
10-23 20:30
美股大行评级 | 最高186美元！戴尔科技或多家机构上调目标价； 高盛上调超微公司目标价至210美元
今日重点评级关注：富国银行：维持Kyverna Therapeutics"超配"评级，目标价从24美元升至27美元；Chardan Capital：维持Oculis Holding"买入"评级，目标价从33美元升至51美元
10-09 10:51
What 6 Analyst Ratings Have To Say About Lantheus Holdings
6 analysts have shared their evaluations of Lantheus Holdings (NASDAQ:LNTH) dur...
10-09 06:01
